Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can be associated with blood cancers, particularly multiple myeloma as well as lymphomas or chronic lymphocytic leukemia.

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Stand Up To Cancer® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a ...

“We are delighted with the robust sales growth in the third quarter, during which we have continued to increase commercial capacity and deliver CARVYKTI to more multiple myeloma patients around the ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.